Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,751,873
  • Shares Outstanding, K 46,754
  • Annual Sales, $ 4,650 K
  • Annual Income, $ -70,510 K
  • 60-Month Beta 2.43
  • Price/Sales 368.82
  • Price/Cash Flow N/A
  • Price/Book 4.31
Trade CLDX with:

Options Overview Details

View History
  • Implied Volatility 73.40% ( -0.77%)
  • Historical Volatility 87.29%
  • IV Percentile 6%
  • IV Rank 2.53%
  • IV High 260.95% on 06/30/22
  • IV Low 68.53% on 03/22/22
  • Put/Call Vol Ratio 0.04
  • Today's Volume 354
  • Volume Avg (30-Day) 509
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 23,843
  • Open Int (30-Day) 36,189

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.51
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -26.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.58 +43.53%
on 07/12/22
37.69 -6.38%
on 08/08/22
+8.55 (+31.99%)
since 07/08/22
3-Month
19.85 +77.73%
on 06/13/22
37.69 -6.38%
on 08/08/22
+7.51 (+27.04%)
since 05/09/22
52-Week
19.85 +77.73%
on 06/13/22
57.20 -38.32%
on 10/04/21
-11.58 (-24.71%)
since 08/09/21

Most Recent Stories

More News
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CLDX : 35.28 (-5.84%)
IBRX : 4.34 (-2.91%)
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2...

CLDX : 35.28 (-5.84%)
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BMRN : 95.70 (unch)
CLDX : 35.28 (-5.84%)
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

CLDX : 35.28 (-5.84%)
BEAM : 60.96 (-4.29%)
ANIK : 22.56 (-3.84%)
APLS : 64.29 (+3.14%)
Billionaire Andreas Halvorsen Bets Big on These 2 High-Upside Stocks

Even after some recent positive trading sessions, the stock markets are still registering heavy losses this year. The S&P is down 18%, and the NASDAQ remains in bear territory with a 26% year-to-date loss....

DNA : 3.13 (-3.40%)
CLDX : 35.28 (-5.84%)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX) and Intercept Pharma (ICPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Celldex (CLDX – Research Report) and Intercept Pharma (ICPT – Research Report). Celldex (CLDX) In a report released...

CLDX : 35.28 (-5.84%)
ICPT : 16.66 (-1.13%)
Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?

The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

CLDX : 35.28 (-5.84%)
Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CLDX : 35.28 (-5.84%)
PBYI : 3.65 (+4.58%)
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.

CLDX : 35.28 (-5.84%)
AGLE : 0.4125 (-3.40%)
LPTX : 1.0900 (-6.03%)
DTIL : 1.5300 (-4.97%)
SVB Securities Thinks Celldex’s Stock is Going to Recover

In a report issued on July 1, Thomas Smith from SVB Securities maintained a Buy rating on Celldex (CLDX – Research Report), with a price target of $68.00. The company's shares closed last Friday at $22.70,...

CLDX : 35.28 (-5.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 40.13
2nd Resistance Point 38.82
1st Resistance Point 37.05
Last Price 35.28
1st Support Level 33.98
2nd Support Level 32.67
3rd Support Level 30.90

See More

52-Week High 57.20
Fibonacci 61.8% 42.93
Fibonacci 50% 38.53
Last Price 35.28
Fibonacci 38.2% 34.12
52-Week Low 19.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar